192 related articles for article (PubMed ID: 33647240)
21. Pharmacokinetic interaction profile of riociguat, a new soluble guanylate cyclase stimulator, in vitro.
Rickert V; Haefeli WE; Weiss J
Pulm Pharmacol Ther; 2014 Aug; 28(2):130-7. PubMed ID: 24657506
[TBL] [Abstract][Full Text] [Related]
22. Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment.
Huang X; Pearce R; Omenn GS; Zhang Y
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209110
[TBL] [Abstract][Full Text] [Related]
23. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
Molecules; 2020 May; 25(10):. PubMed ID: 32408547
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.
Doricakova A; Theile D; Weiss J; Vrzal R
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):49-59. PubMed ID: 27678410
[TBL] [Abstract][Full Text] [Related]
26. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
27. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
28. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
[TBL] [Abstract][Full Text] [Related]
29. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist.
Fujioka K; Fekry MI; Rumsey JM; Steiner T; Thompson D; Mousa SA
Clin Transl Sci; 2023 Jun; 16(6):987-1001. PubMed ID: 36967488
[TBL] [Abstract][Full Text] [Related]
30. Effects of adrenolytic mitotane on drug elimination pathways assessed in vitro.
Theile D; Haefeli WE; Weiss J
Endocrine; 2015 Aug; 49(3):842-53. PubMed ID: 25542188
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.
Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
Clin Pharmacol Ther; 2018 Dec; 104(6):1182-1190. PubMed ID: 29569723
[TBL] [Abstract][Full Text] [Related]
32. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.
Weiss J; Gajek T; Köhler BC; Haefeli WE
Pharmaceutics; 2016 Feb; 8(1):. PubMed ID: 26927160
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
[TBL] [Abstract][Full Text] [Related]
35. Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transporters.
Weiss J; Kocher J; Mueller C; Rosenzweig S; Theile D
Biopharm Drug Dispos; 2017 Dec; 38(9):517-525. PubMed ID: 28865089
[TBL] [Abstract][Full Text] [Related]
36. Herb⁻Drug Interaction Potential of Anti-Borreliae Effective Extracts from
Weiss J
Molecules; 2018 Dec; 24(1):. PubMed ID: 30602711
[TBL] [Abstract][Full Text] [Related]
37. CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides.
Sergent T; Dupont I; Jassogne C; Ribonnet L; van der Heiden E; Scippo ML; Muller M; McAlister D; Pussemier L; Larondelle Y; Schneider YJ
Toxicol Lett; 2009 Feb; 184(3):159-68. PubMed ID: 19070657
[TBL] [Abstract][Full Text] [Related]
38. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.
Gertz M; Cartwright CM; Hobbs MJ; Kenworthy KE; Rowland M; Houston JB; Galetin A
Pharm Res; 2013 Mar; 30(3):761-80. PubMed ID: 23179780
[TBL] [Abstract][Full Text] [Related]
39. Gancao (Glycyrrhizae Radix) provides the main contribution to Shaoyao-Gancao decoction on enhancements of CYP3A4 and MDR1 expression via pregnane X receptor pathway in vitro.
Feng D; Tang T; Fan R; Luo J; Cui H; Wang Y; Gan P
BMC Complement Altern Med; 2018 Dec; 18(1):345. PubMed ID: 30594244
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
